All lobbying filings

TIBER CREEK GROUP

Lobbying for ALNYLAM PHARMACEUTICALS, INC. · Biopharmaceuticals.

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Massachusetts · House · Senate · $60,000.00 income · posted Jan 20, 2026

Official filing document

Bills named in this filing 3

HR 946
ORPHAN Cures Act
S 1862
ORPHAN Cures Act
HR 1672
Maintaining Investments in New Innovation Act

Lobbying activity 1

Medicare/Medicaid

Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.